Wealth Alliance Has $228,000 Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

Wealth Alliance lowered its stake in Exact Sciences Co. (NASDAQ:EXAS) by 10.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,082 shares of the medical research company’s stock after selling 350 shares during the period. Wealth Alliance’s holdings in Exact Sciences were worth $228,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of EXAS. True Wealth Design LLC acquired a new position in shares of Exact Sciences during the fourth quarter worth $30,000. Wolff Wiese Magana LLC lifted its holdings in shares of Exact Sciences by 459.5% during the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock worth $31,000 after purchasing an additional 340 shares during the period. KB Financial Partners LLC acquired a new position in shares of Exact Sciences during the second quarter worth $32,000. BluePath Capital Management LLC acquired a new position in shares of Exact Sciences during the third quarter worth $33,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Exact Sciences during the third quarter worth $34,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Trading Down 4.0 %

EXAS opened at $60.96 on Friday. Exact Sciences Co. has a 1-year low of $56.05 and a 1-year high of $100.77. The company has a current ratio of 2.32, a quick ratio of 2.07 and a debt-to-equity ratio of 0.74. The company has a market cap of $11.07 billion, a P/E ratio of -53.47 and a beta of 1.25. The company has a fifty day moving average price of $63.42 and a two-hundred day moving average price of $65.06.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.26. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The firm had revenue of $646.89 million during the quarter, compared to the consensus estimate of $638.83 million. During the same period in the previous year, the firm posted ($0.72) earnings per share. The business’s revenue was up 17.0% compared to the same quarter last year. Analysts predict that Exact Sciences Co. will post -0.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EXAS has been the topic of a number of recent research reports. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 22nd. Citigroup restated a “buy” rating and issued a $100.00 target price on shares of Exact Sciences in a report on Wednesday, April 3rd. Benchmark upgraded shares of Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 target price on the stock in a report on Tuesday, January 2nd. Canaccord Genuity Group dropped their target price on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Finally, TheStreet lowered shares of Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Exact Sciences has a consensus rating of “Moderate Buy” and an average price target of $97.44.

Insider Buying and Selling at Exact Sciences

In other news, EVP Sarah Condella sold 965 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $61.43, for a total transaction of $59,279.95. Following the completion of the sale, the executive vice president now directly owns 70,489 shares of the company’s stock, valued at $4,330,139.27. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Kevin T. Conroy sold 14,791 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $61.43, for a total transaction of $908,611.13. Following the completion of the sale, the chief executive officer now directly owns 1,224,357 shares of the company’s stock, valued at $75,212,250.51. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Sarah Condella sold 965 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $61.43, for a total transaction of $59,279.95. Following the sale, the executive vice president now directly owns 70,489 shares of the company’s stock, valued at $4,330,139.27. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,113 shares of company stock valued at $4,165,273. Corporate insiders own 1.30% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.